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Background: Controlling canine vector-borne diseases (CVBD) is a major concern, since some of these diseases are
serious zoonoses. This study was designed to determine seropositivity rates in Spain for agents causing the following
five CVBD: leishmaniosis (Leishmania infantum: Li), heartworm (Dirofilaria immitis: Di), ehrlichiosis (Ehrlichia canis: Ec),
anaplasmosis (Anaplasma phagocytophilum/Anaplasma platys: An) and Lyme disease (Borrelia burgdorferi: Bb).
Methods: Anti-An, -Bb, and -Ec antibodies and the Di antigen were determined using the 4DX SNAPW Test (IDEXX
Laboratories) and anti-L. infantum (Li) antibodies using the Leishmania SNAPW Test (IDEXX Laboratories) in blood and/or
serum samples.
Results: Among 1100 dogs examined, overall seropositivity rates were: Li (15.7%), Ec (5%), An (3.1%), Di (1.25%) and
Bb (0.4%). While seropositivity towards Bb and Di was similar in all geographic regions, rates were significantly higher
in the east of Spain (8.3%) for An, significantly higher in the north (20%) for Ec, and significantly higher in the Southeast
(46.6%) and South (27.4%), and significantly lower in the north (0%) for Li.
No statistical associations were observed between sex and the CVBD analyzed (p≥ 0.05) while the following
associations with other variables were detected: a higher seropositivity to Ec (40%) and Bb (6.7%) in dogs under one year
of age compared with adults (p < 0.05); and a higher seropositivity to An and Li in dogs that lived outdoors versus
indoors (p = 0.01; p < 0.001, respectively). Seropositivity rates of 2.1%, 0%, 1.7%, 0.5% and 4.2% were recorded
respectively for An, Bb, Ec, Di and Li in dogs with no clinical signs (n = 556) versus 3.8%, 0.6%, 7.5%, 1.8% and 25.9% for
those with signs (n = 507) suggestive of a CVBD.
Conclusion: The data obtained indicate a risk for dogs in Spain of acquiring any of the five CVBD examined. Veterinarians
in the different regions should include these diseases in their differential diagnoses and recommend the use of repellents
and other prophylactic measures to prevent disease transmission by arthropod vectors. Public health authorities also need
to become more involved in the problem, since some of the CVBD examined here also affect humans.
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The term canine vector-borne diseases (CVBD) includes a
wide variety of diseases of infectious or parasitic aetiology
whose agents are transmitted by ectoparasites such as
ticks, fleas, lice, mosquitoes and sand flies [1]. Controlling
these infectious agents is important because some are
responsible for serious diseases in humans (e.g. Anaplasma
phagocytophilum, Bartonella spp., Borrelia burgdorferi,* Correspondence: gmiro@ucm.es
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ever, their control can be extremely complex since they
show a wide geographical distribution, and clinical signs in
infected dogs can vary significantly [3,4].
In addition, there is evidence to suggest that changing
factors linked to climate and the environment could deter-
mine the expansion of the current geographical distribution
ranges of these diseases and their arthropod vectors [5-9].
The transport of infected dogs from endemic areas has also
been attributed an important role in the spread of CVBD
to the north of Europe [10,11]. Owing to an increase in this
transport due to new habits such as travelling with dogs or
adopting animals from other countries, the epidemiologicald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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across the Iberian Peninsula including Portugal, has
changed considerably [12-14].
CVBD may show no specific clinical signs or clinical-
pathological abnormalities, or alternatively may present
a varied clinical picture making the diagnosis of a CVBD
extremely complex. Animals with subclinical infection
have been described to show an increased risk of disease
transmission [15,16].
Anaplasma platys and A. phagocytophilum (An) are
the aetiological agents of anaplasmosis, which affects
a wide range of vertebrate hosts (rodents, dogs,
humans). A. phagocytophilum is transmitted by ticks
of the genus Ixodes and A. platys by the tick
Rhipicephalus sanguineus. Both pathogens infect dogs
in which the clinical picture ranges from subclinical
disease to acute illness [17]. A. phagocytophilum can
also infect humans causing febrile syndrome [18]. The
reported seroprevalence of Anaplasma spp. in Spain has
ranged from 5 to 19% for Galicia, Catalonia, Balearic
Islands and Castilla-León [19-21].
Lyme disease is an infectious disease caused by spiro-
chetes belonging to the Borrelia burgdorferi (Bb) sensu
lato complex, transmitted by ticks of the genus Ixodes.
Lyme disease shows a worldwide distribution, although its
incidence is increasing in North America and Europe
because of its association with this vector [22-24]. Bb
affects a wide range of hosts, mainly humans and dogs. In
humans, Lyme disease can produce chronic weakness with
nonspecific clinical signs (fever, muscle and joint pain).
Though few dogs show clinical signs, most are subclinical
reservoirs [25,26] and can be used as sentinels for this
infection. In Spain, dogs seropositive for B. burgdorferi
have been detected in Galicia (6.3%) [20], Mallorca (1.3%)
[19] and Castilla -León (2.1 to 21%) [27-29].
Ehrlichia canis (Ec), an intracellular Gram-negative
bacterium that infects monocytes, is the causative agent
of canine monocytic ehrlichiosis, and is transmitted by
the tick Rhipicephalus sanguineus [30]. The disease is
characterized by three stages of varying severity. The
acute stage produces clinical signs such as apathy, de-
pression, anorexia, dyspnoea, fever, lymphadenopathy,
splenomegaly, petechiae and echymotic haemorrhage
in the skin and the mucous membranes, epistaxis,
and vomiting. Laboratory abnormalities are usually
thrombocytopenia, leucopenia and mild to moderate
normocytic, normochromic and non-regenerative anaemia.
The second stage is subclinical with clinical-pathological
abnormalities such as thrombocytopenia, anaemia or
hyperproteinemia. The third or chronic stage is character-
ized by a very complex clinical picture: haemorrhage, weak-
ness, apathy, sustained weight loss, fever, lymphadenopathy,
splenomegaly and peripheral oedema in the hind limbs
and scrotum and a wide variety of clinical-pathologicalabnormalities [31,32]. In Spain, the seroprevalence of Ec in
dogs ranges from 3.1 to 19%, with cited rates of 3.1-6.5%
for Galicia, Madrid and Zaragoza [20,33,34] and higher
rates for Mediterranean regions (Catalonia, Valencia,
Baleares) [19,35,36] and Castilla-León (12-20%) [35].
Dirofilaria immitis (Di) is a filarial worm transmitted
by mosquitoes (Culicidae) to carnivores and other hosts.
Since the vector is not very host specific, many mammals
can become infected including humans [37]. D. immitis is a
cosmopolitan parasite, mainly found in southern European
countries including Spain, where it is endemic in the
regions Valencia, Balearic Islands, Andalucia, Aragon and
the Canary Islands with prevalences of 6.3-67.02% [38-42].
Lower prevalences have been reported for other regions,
although recently cases have been detected in two northern
provinces: La Rioja (12%) and La Coruña (4.2%) [43,44]. D.
immitis, also known as heartworm, mainly affects dogs but
has also been detected in cats [45]. In dogs, the course of
disease is chronic due to changes in the pulmonary arteries
and lung parenchyma [46]. In humans, the parasite cannot
complete its whole life cycle, yet produces a serious infec-
tion in which parasitic granulomas can be observed in the
lung parenchyma [47].
Canine leishmaniosis (CanL), a zoonotic disease
endemic in southern Europe caused by the protozoan
Leishmania infantum (Li), is transmitted to humans and
animals by blood-sucking phlebotomine sand flies
[48,49]. Until recently, CanL was considered to be
limited to the Mediterranean basin, with an estimated
seroprevalence in Spain ranging from 3% in the north
[50] to 34.6% for Malaga province on the south coast
[51]. Northern Spain was considered a non-endemic area
but CanL and its sand fly vectors have been detected in the
northeast and northwest where the disease was previously
unknown [50,52-54]. At our latitude, dogs are considered
the main reservoir for human infection [55,56]. Clinical
CanL shows a wide spectrum of clinical signs and severity
because of the many pathogenic mechanisms involved and
the particular immune response produced in the host [57].
The main clinical signs of CanL are one or more of the
following: weight loss, lethargy, muscular atrophy, anaemia,
lymphadenomegaly, splenomegaly, epistaxis, diarrhoea,
renal disorders, ocular lesions, polyarthritis, onycogryphosis
and skin lesions [58-60]. In endemic areas, a high propor-
tion of clinically healthy dogs are able to transmit the infec-
tion causing a serious public health problem [61]. In
Europe, human infection with L. infantum is observed
mainly in children and immunocompromised adults,
but a recent outbreak (2010) in southwest Madrid (Spain)
indicates the epidemiology of this disease is complex and
subject to constant change [62,63].
Information emerging from Spain on some of these vec-
tor borne diseases has been limited. Most studies have
addressed canine leishmaniosis in the Mediterranean basin
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Borrelia and Anaplasma infection in specific areas of
the country.
The present study was designed to establish seropositiv-
ity rates and epidemiological associations for these five
CVBD by determining antibodies against Anaplasma spp.
(An), Borrelia burgdorferi (Bb), Ehrlichia canis (Ec), and
Leishmania infantum (Li) and the Dirofilaria immitis (Di)
antigen in dogs from different Spanish regions.
Methods
Bioclimatic characteristics of the study area
The survey was carried out in seven different eco-
epidemiological regions of Spain. The Iberian Peninsula
shows two main regions of flora and vegetation, the
Mediterranean and Eurosiberian regions. This last region
covers the north of Spain where climate and vegetation
are typically oceanic, with warm summers and cool
winters and rainfall evenly distributed all year round.
The rest of the peninsula falls within the Mediterranean
region. Here, summers are dry and hot, and most rainfall
occurs in autumn and spring. Moreover, coastal areas
show a milder, more humid climate, and mountain
ranges have a shielding effect from an oceanic influence
determining a climate of extremely cold winters and very
hot summers.
Veterinary clinics and dogs
The study was carried out in accordance with the
International Guiding Principles for Biomedical Research
Involving Animals, issued by the Council for the
International Organizations of Medical Sciences. The
owners of the dogs enrolled were previously informed
about the study protocol.
The dogs examined were 1100 owned dogs attending 57
veterinary clinics in central (187 dogs; 7 clinics), eastern
(90 dogs; 5 clinics), southern (75 dogs; 5 clinics),
southeastern (105 dogs; 5 clinics), northern (15 dogs; 1
clinic), northeastern (465 dogs; 22 clinics) and northwestern
(163 dogs; 11 clinics) Spain (see Figure 1).
Dogs were subjected to the same protocol to compile a
brief clinical record based on a questionnaire and physical
examination. Blood samples were collected from all dogs.
The data collected were correlated with age, sex, abode
(indoors, outdoors or mixed), and the presence of clinical
signs compatible with any CVBD. The dogs were 6 months
to 18 years of age; 593 were male (489 entire, 104
neutered) and 507 female (405 entire, 102 neutered).
Serologic testing
Anti-An, -Bb, and -Ec antibodies and the Di antigen
were determined using the 4DX SNAPW Test (IDEXX
Laboratories) and anti-L. infantum (Li) antibodies usingthe Leishmania SNAPW Test (IDEXX Laboratories) in
blood and/or serum samples.
Statistical analysis
Seropositivity rates were compared according to age, sex,
abode and the presence of clinical signs. Associations
between CVBD-agent seropositivity and the remaining vari-
ables were assessed using the chi-squared test. All statistical
tests were performed using SPSS 19.0 software (SPSS Inc.,
Chicago, IL, USA). Significance was set at p≤ 0.05.
Results
Overall seropositivity rates for the five CVBD agents
were: Li (15.7%), Ec (5%), An (3.1%), Di (1.25%) and Bb
(0.4%). Rates obtained by geographic region are shown in
Table 1. Seropositivity to the Bb antibody and Di antigen
was similar in the seven regions. Seropositivity to An was
significantly higher (8.3%) in the east than the remaining
regions (0-5%), the rate for Ec was significantly higher in
the north (20%) and that for Li was significantly higher in
the south (46.6%) and southeast (27.4%). In the north of
Spain, no dog tested was Li seropositive (Table 1).
No associations were observed between sex and any
CVBD (p ≥ 0.05). Seropositivity towards Ec (40%) and Bb
(6.7%) was higher in dogs under one year of age compared
to adults (p < 0.05), while no differences in the rates
recorded for An, Di or Li were detected between the two
age groups.
Seropositivity to An and Li was significantly higher for
dogs that lived outdoors compared to indoors. No link
was detected between the seropositivity rate observed
for Bb, Ec and Di, and place of abode.
When stratified by the presence or absence of clinical
signs, percentages of An, Bb, Ec, Di and Li seropositive
dogs were 2.1%, 0%, 1.7%, 0.5% and 4.2% for the subset
of dogs with no clinical signs (n = 556), and 3.8%, 0.6%,
7.5%, 1.8% and 25.9% for those with clinical signs compat-
ible with CVBD respectively (n = 507) (Table 2). The main
clinical signs described by the veterinarians were: apathy,
anorexia, anaemia, lymphadenomegaly, digestive disorders,
skin lesions characterized by alopecia, seborrhoeic
dermatitis, erythema, scaling and hyperkeratosis, as well
as ulcerative lesions, and onychogryposis.
In addition, seropositivity rates for Li and Ec were
correlated with the presence of clinical signs in the
dogs examined. No correlation was detected, however,
between seropositivity for Bb, An and Di and the
presence of clinical signs.
Discussion
This study is the most complete survey of CVBD-agent
seropositivity conducted in Spain. Most prior studies
have been limited to a single region [21]. Overall, 37.1%
of the dogs were seropositive for at least one of the five
Table 1 Seropositivity for the CVBD studied by geographical region
Geographic region CVBD
Positive/Total (%)
An Bb Ec Di Li
Central (n = 187) 9/180 (5) 0/176 (0) 9/176 (5.1) 4/176 (2.3) 10/157 (6.4)
Northeast (n = 465) 9/451 (2) 1/451 (0.2) 23/451 (5.1) 3/451 (0.7) 60/434 (13.8)
East (n = 90) 6/72 (8.3) * 0/73 (0) 6/73 (8.2) 2/73 (2.7) 13/69 (18.8)
Southeast (n = 105) 2/45 (4.4) 0/30 (0) 1/33 (3) 0/31 (0) 41/88 (46.6) **
South (n = 75) 2/68 (2.9) 0/68 (0) 4/68 (5.9) 3/68 (4.4) 20/73 (27.4) **
Northwest (n = 163) 2/143 (1.4) 3/143 (2.1) 2/143 (1.4) 0/142 (0) 12/159 (7.5)
North (n = 15) 0/15 (0) 0/15 (0) 3/15 (20) * 0/15 (0) 0/15 (0) **
Total (n = 1100) 30/976 (3.1) 4/956 (0.4) 48/959 (5) 12/957 (1.25) 156/995 (15.7)
p value p = 0.04 p = 0.07 p = 0.04 p = 0.06 p < 0.001









Figure 1 CVBD seropositivity recorded for seven Spanish geographical regions.
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Table 2 Seropositivity for CVBD according to the epidemiological variables analyzed
Epidemiological variable CVBD
Positive/Total (%)
An Bb Ec Di Li
Age (years) <1 2/17 (11.8) 1/15 (6.7)** 6/15 (40)** 0/15 (0) 0/14 (0)
1-3 12/369 (3.2) 1/361 (0.3) 7/362 (1.9) 2/361 (0.5) 60/370 (16.2)
3-7 7/269 (2.6) 0/261 (0) 12/261 (4.6) 2/262 (0.8) 50/270 (18.5)
>7 7/307 (2.3) 2/305 (0.6) 23/307 (7.5) 6/305 (2) 44/327 (13.5)
Unknown 2/14 (14.3) 0/14 (0) 0/14 (0) 2/14 (14.3) 2/14 (14.3)
p value p = 0.14 p = 0.001 p < 0.001 p = 0.3 p = 0.14
Sex Male 21/531 (4) 3/526 (0.6) 23/528 (4.4) 9/527 (1.7) 94/546 (17.2)
Female 9/445 (2) 1/430 (0.2) 25/431 (5.8) 3/430 (0.7) 62/449 (13.8)
p value p = 0.08 p = 0.16 p = 0.4 p = 0.14 p = 0.16
Clinical signs Asymptomatic 9/433 (2.1) 0/416 (0) 7/417 (1.7) 2/416 (0.5) 19/449 (4.2)
Symptomatic 19/506 (3.8) 3/503 (0.6) 38/505 (7.5)** 9/504 (1.8) 133/513 (25.9)**
Unknown 2/37 (5.4) 1/37 (2.7) 3/37 (8.1) 1/37 (2.7) 4/33 (12.1)
p value p = 0.13 p = 0.11 p < 0.001 p = 0.07 p < 0.001
Place of abode Indoor 6/360 (1.7) 0/346 (0) 14/346 (4) 2/346 (0.6) 26/354 (7.3)
Outdoor 18/357 (5)* 1/355 (0.3) 22/355 (6.2) 5/355 (1.4) 86/362 (23.8)**
Mixed 5/256 (2) 3/252 (1.2) 12/255 (4.7) 5/253 (2) 43/276 (15.6)
Unknown 1/3 (5.2) 0/3 (0) 0/3 (0) 0/3 (0) 1/3 (5.2)
p value p = 0.01 p = 0.07 p = 0.23 p = 0.28 p < 0.001
* p < 0.05; **p < 0.001. Abbreviations: An, Anaplasma phagocytophilum/Anaplasma platys; Bb, Borrelia burgdorferi; Ec, Ehrlichia canis; Di, Dirofilaria immitis; Li,
Leishmania infantum.
Miró et al. Parasites & Vectors 2013, 6:117 Page 5 of 9
http://www.parasitesandvectors.com/content/6/1/117CVBD agents examined. The highest seropositivity rate
detected was that of Li (15.7%) and the lowest Bb (0.4%),
the seropositivity rate for each of these CVBD pathogens
varying according to the geographic region. Despite
differences detected in seropositivity to each CVBD-agent
among each of the seven regions, the travel history of each
dog was not included in the questionnaire, such that we
cannot rule out the possibility that dogs were infected
outside their home region [14].
The present study examines several epidemiological var-
iables to assess possible associations with CVBD-agent
seropositivity. No link was detected between sex and each
CVBD (p ≥ 0.05) although seropositivity rates for Ec (40%)
and Bb (6.7%) were higher in dogs under one year of age
compared with adults (p < 0.05). These data suggest a
need for further studies designed to determine the effects
of age on CVBD-agent seropositivity since we only
examined 17 young dogs.
No significant correlation was detected in our study
between the presence of clinical signs in a dog and its
positivity for Bb, An or Di. In contrast, Li or Ec positiv-
ity was correlated with the presence of clinical signs in
the dogs examined (p < 0.05). This finding is consistent
with reports indicating that clinical signs are commonly
observed in dogs infected with L. infantum and E. canis
[14,16,64,65].CVBD have been correlated with the presence of
vectors such that prevalences should be higher in dogs
living outdoors due to their greater cumulative exposure
to the agents these vectors transmit. However, we
detected no association between positivity for Bb, Ec and
Di and place of abode, though dogs living outside
showed a higher rate of An and Li. Seropositivity towards
An was significantly higher in dogs living outdoors, in
agreement with data obtained in dog shelters in northwest
(45.3%) and central (19%) Spain [20,21]. It would be inter-
esting to collect information on whether the dogs were
protected with an ectoparasiticidal agent since some of
these insecticides are able to prevent CVBD [66-70].
Macrocyclic lactones have also been found to be effective
against canine heartworm [46].
In Europe, A. phagocytophilum is transmitted by the
tick Ixodes ricinus, whose distribution range is limited to
areas of high humidity and cold temperatures, while A.
platys could be transmitted by Rhipicephalus sanguineus,
widely distributed across the Iberian Peninsula. Our re-
sults revealed a high seropositivity for this agent in eastern
(8.3%) and central (5%) Spain, and a lower seropositivity
in the north (0-2%). In prior studies conducted on dogs
attending veterinary clinics in the northwest and east of
Spain, similar rates of 5% and 11.5%, respectively, have
been reported [19,20]. Despite the good sensitivity and
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Anaplasma (99.1% and 100%, respectively), serological
cross-reactivity between A. phagocytophilum and A. platys
has been described in experimentally infected dogs [71].
Thus, PCR is needed to identify the Anaplasma species.
Our results could therefore indicate exposure to the
Anaplasma genus with no information provided at the
species level. So far, A. phagocytophilum has not been
isolated in Spanish dogs. It is likely that the antibodies
detected in this study were anti-A. platys antibodies since
we noted a higher seropositivity to An in areas where the
presence of R. sanguineus is common. It is also true that I.
ricinus is the common vector of B. burgdorferi and A.
phagocytophilum, yet we found no An/Bb co-infections.
However, dogs from some regions could be infected with
A. phagocytophilum since this agent has been isolated
from Ixodes ticks [72,73] and has also been detected in
sheep, goats, cows, deer, birds [73-75] and even human
beings [76,77].
Antibodies against Bb were only detected in four dogs,
three in the northwest (2.1%) and one in the northeast
(0.2%). The Snap 4DX kit only detects these antibodies
during active infection [78] such that this could explain
the low seroprevalence recorded. Other serological studies
in which the Snap 3DX or 4DX methods were used have
provided similar results [19,21]. Our data indicate signifi-
cantly higher seropositivity for Bb in the younger dogs
(<1 year), though this finding requires confirmation since
our study only included 17 young dogs.
The bacterium Ec is transmitted by R. sanguineus. This
tick is the most common tick found in dogs which explains
the wide distribution of the disease [79]. R. sanguineus has
been detected across Spain though we observed a signifi-
cantly higher seropositivity to Ec in the north, where 6 out
of 15 dogs were seropositive, while the overall prevalence
of Ec was 5%. The low number of dogs surveyed precludes
reliable estimates of the real prevalence of this disease.
However, the higher seropositivity rate detected in the
north could reflect the fact that E. canis infection is not
limited to dogs, and that other wild canids (wolves, foxes,
coyotes) may serve as reservoirs of infection [80]. Effect-
ively, in northern Spain (Asturias), wild canids could live in
close contact with domestic canids. There is also evidence
that the prevalence of Ec is higher in rural areas or among
stray dogs [20] than in urban areas [81]. Other authors
have reported a similar Ec seroprevalence for different
areas of the country in household dogs (3.13- 16.7%)
[19,20] along with a higher seroprevalence (54.7%) in stray
dogs from the northwest of Spain [20].
D. immitis antigen was detected in 1.25% of the dogs
examined here. Higher rates were recorded for central
(2.3%) and eastern (2.7%) regions of the country while
Di antigen was not detected in dogs from the north and
northwest. It is known that climate and environmentalfactors determine the geographical distribution of its vec-
tor (Culicidae), allowing it to complete its life cycle and
consequently the life cycle of Di [42,82]. In Spain, similar
surveys have identified Di in large areas of the country,
often in irrigated zones [42]. A high prevalence of Di has
been reported in the Canary Islands (19.2-67.02%)
[38,40,41,83], Mediterranean coast (6.3-39%)[84] and
southern regions (8.5-36.7%) [38,39]. At present, while in
certain areas (e.g. Gran Canaria) prevalence is decreasing
probably due to preventive measures [41,42], in other
areas where Di was considered non-endemic (La Rioja
and La Coruña), the first cases of canine dirofilariosis have
been detected [43,44,85]. A possible explanation for the
lower prevalences detected here is that the ELISA test can
give rise to false negatives in dogs with low heartworm
burdens or in blood samples from dogs infected only by
male worms [86]. Besides, these types of study are difficult
to compare due to differences in the diagnostic techniques
used (PCR, agglutination test, ELISA, etc.), the size and
origin of samples, and the study season.
As expected, seropositivity towards L. infantum was
the highest of all the CVBD-agents analyzed (15.7%). Li
antibodies were detected in all the geographic regions
except the north, and higher rates were recorded for the
south (27.4%) and southeast (46.6%). Our Li seropositiv-
ity map is similar to those emerging from other Spanish
surveys [65,87,88]. Other studies conducted in Spain
[50,89] have detected a higher seroprevalence in some
northern areas. Such differences between studies could
be attributable to the different population analyzed, the
sampling season and the diagnostic technique used.
Among the dogs testing seropositive for Li, 85.2%
(133/156) showed clinical signs of leishmaniosis in the
physical exam performed by the veterinarians (Table 2).
This can be explained by the fact that CanL is well known
to Spanish practitioners despite the wide variety of clinical
signs this disease can show [53,90]. In addition, Li sero-
positivity was significantly higher in the subset of dogs that
lived outdoors compared to those living at home or even
both indoors and outdoors. The explanation for this could
lie in the increased exposure of dogs that spend more time
outdoors to phlebotomines [65,88,91]. Arthropod vector
distribution and density cause differences in the regional
distribution of CVBD-agent seropositivity. To understand
the potential role of the vector, knowledge of its environ-
mental requirements is fundamental. There is indeed a
need for research targeted at the prevention, diagnosis,
treatment and prevention of CBVD. Information on the
prevalence and geographical distribution of these infections
is essential for planning control measures and their
surveillance thereafter. This preliminary overview of
the current situation in Spain requires further work
to complete the prevalence map of agents causing
CBVD in this country.
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The findings of this study reveal that dogs in Spain are
at risk of acquiring any of the five CVBD examined
(leishmaniosis, heartworm, ehrlichiosis, anaplasmosis
and Lyme disease). They also indicate that veterinarians
across Spain need to include these diseases in their
differential diagnosis and recommend the use of repellents
along with prophylactic measures to prevent disease trans-
mission by arthropod vectors. In addition, greater involve-
ment on the part of public health authorities is needed
given that some of the CVBD detected can be transmitted
to humans.
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